Immunic, inc. to participate in investor conferences in september

New york , sept. 1, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor conferences in september: september 7-8: citi's 17th annual biopharma conference.
IMUX Ratings Summary
IMUX Quant Ranking